Trial Profile
Injection of Autologous CD34-Positive Cells for Neovascularization and Symptom Relief in Patients With Myocardial Ischemia.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs CLBS-14 (Primary)
- Indications Angina pectoris; Myocardial ischaemia
- Focus Adverse reactions
- 06 Mar 2018 According to a Caladrius Biosciences media release, Douglas W. Losordo, MD, FACC, FAHA, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer of Caladrius is the principal investigator of the study
- 05 Nov 2010 New trial record.